#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	time	new	coref	34-12[236_0]
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Currently , we expect foods to satisfy hunger while delivering nutrients essential for humans , but their task is also the prevention of diet-related diseases .
3-1	17-26	Currently	_	_	_	_
3-2	27-28	,	_	_	_	_
3-3	29-31	we	person	acc	ana	11-2
3-4	32-38	expect	_	_	_	_
3-5	39-44	foods	substance	new	coref	4-1[12_0]
3-6	45-47	to	_	_	_	_
3-7	48-55	satisfy	_	_	_	_
3-8	56-62	hunger	abstract	new	_	_
3-9	63-68	while	_	_	_	_
3-10	69-79	delivering	_	_	_	_
3-11	80-89	nutrients	substance[6]	new[6]	coref	5-17[20_6]
3-12	90-99	essential	substance[6]	new[6]	_	_
3-13	100-103	for	_	_	_	_
3-14	104-110	humans	person	new	ana	3-17
3-15	111-112	,	_	_	_	_
3-16	113-116	but	_	_	_	_
3-17	117-122	their	person|abstract[9]	giv|new[9]	coref|coref	3-21[10_9]|3-21[10_9]
3-18	123-127	task	abstract[9]	new[9]	_	_
3-19	128-130	is	_	_	_	_
3-20	131-135	also	_	_	_	_
3-21	136-139	the	abstract[10]	giv[10]	_	_
3-22	140-150	prevention	abstract[10]	giv[10]	_	_
3-23	151-153	of	abstract[10]	giv[10]	_	_
3-24	154-166	diet-related	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-25	167-175	diseases	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-26	176-177	.	_	_	_	_

#Text=Functional foods play a significant role in this case .
4-1	178-188	Functional	substance[12]	giv[12]	ana	5-3[0_12]
4-2	189-194	foods	substance[12]	giv[12]	_	_
4-3	195-199	play	_	_	_	_
4-4	200-201	a	abstract[13]	new[13]	_	_
4-5	202-213	significant	abstract[13]	new[13]	_	_
4-6	214-218	role	abstract[13]	new[13]	_	_
4-7	219-221	in	abstract[13]	new[13]	_	_
4-8	222-226	this	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-9	227-231	case	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-10	232-233	.	_	_	_	_

#Text=Due to their beneficial physiological effects , including antioxidant , anticancer , and anti-inflammatory properties , nutrients from marine animals , as well as bioactive components have great potential as ingredients in functional foods .
5-1	234-237	Due	_	_	_	_
5-2	238-240	to	_	_	_	_
5-3	241-246	their	substance|abstract[16]	giv|new[16]	coref|coref|coref|coref	5-33[24_0]|23-22[156_16]|5-33[24_0]|23-22[156_16]
5-4	247-257	beneficial	abstract[16]	new[16]	_	_
5-5	258-271	physiological	abstract[16]	new[16]	_	_
5-6	272-279	effects	abstract[16]	new[16]	_	_
5-7	280-281	,	abstract[16]	new[16]	_	_
5-8	282-291	including	abstract[16]	new[16]	_	_
5-9	292-303	antioxidant	abstract[16]|substance	new[16]|new	coref	14-1
5-10	304-305	,	abstract[16]	new[16]	_	_
5-11	306-316	anticancer	abstract[16]|substance	new[16]|new	_	_
5-12	317-318	,	abstract[16]	new[16]	_	_
5-13	319-322	and	abstract[16]	new[16]	_	_
5-14	323-340	anti-inflammatory	abstract[16]|abstract[19]	new[16]|new[19]	coref	15-16[90_19]
5-15	341-351	properties	abstract[16]|abstract[19]	new[16]|new[19]	_	_
5-16	352-353	,	abstract[16]	new[16]	_	_
5-17	354-363	nutrients	abstract[16]|substance[20]	new[16]|giv[20]	coref	23-13[0_20]
5-18	364-368	from	abstract[16]|substance[20]	new[16]|giv[20]	_	_
5-19	369-375	marine	abstract[16]|substance[20]|animal[21]	new[16]|giv[20]|new[21]	_	_
5-20	376-383	animals	abstract[16]|substance[20]|animal[21]	new[16]|giv[20]|new[21]	_	_
5-21	384-385	,	abstract[16]	new[16]	_	_
5-22	386-388	as	abstract[16]	new[16]	_	_
5-23	389-393	well	abstract[16]	new[16]	_	_
5-24	394-396	as	abstract[16]	new[16]	_	_
5-25	397-406	bioactive	abstract[16]|substance[22]	new[16]|new[22]	_	_
5-26	407-417	components	abstract[16]|substance[22]	new[16]|new[22]	_	_
5-27	418-422	have	_	_	_	_
5-28	423-428	great	abstract[23]	new[23]	_	_
5-29	429-438	potential	abstract[23]	new[23]	_	_
5-30	439-441	as	abstract[23]	new[23]	_	_
5-31	442-453	ingredients	abstract[23]	new[23]	_	_
5-32	454-456	in	abstract[23]	new[23]	_	_
5-33	457-467	functional	abstract[23]|substance[24]	new[23]|giv[24]	_	_
5-34	468-473	foods	abstract[23]|substance[24]	new[23]|giv[24]	_	_
5-35	474-475	.	_	_	_	_

#Text=After filleting , fish processing waste comprises 75 % of the overall fish weight .
6-1	476-481	After	_	_	_	_
6-2	482-491	filleting	abstract	new	_	_
6-3	492-493	,	_	_	_	_
6-4	494-498	fish	animal|abstract[28]	new|new[28]	coref|coref|coref|coref	6-13|7-5[33_28]|6-13|7-5[33_28]
6-5	499-509	processing	abstract|abstract[28]	new|new[28]	coref	8-6[38_0]
6-6	510-515	waste	abstract[28]	new[28]	_	_
6-7	516-525	comprises	_	_	_	_
6-8	526-528	75	quantity[29]	new[29]	_	_
6-9	529-530	%	quantity[29]	new[29]	_	_
6-10	531-533	of	quantity[29]	new[29]	_	_
6-11	534-537	the	quantity[29]|abstract[31]	new[29]|new[31]	_	_
6-12	538-545	overall	quantity[29]|abstract[31]	new[29]|new[31]	_	_
6-13	546-550	fish	quantity[29]|animal|abstract[31]	new[29]|giv|new[31]	coref	8-9
6-14	551-557	weight	quantity[29]|abstract[31]	new[29]|new[31]	_	_
6-15	558-559	.	_	_	_	_

#Text=Approximately 30 % of the waste is in the form of bones and skins .
7-1	560-573	Approximately	quantity[32]	new[32]	ana	9-1[0_32]
7-2	574-576	30	quantity[32]	new[32]	_	_
7-3	577-578	%	quantity[32]	new[32]	_	_
7-4	579-581	of	quantity[32]	new[32]	_	_
7-5	582-585	the	quantity[32]|abstract[33]	new[32]|giv[33]	_	_
7-6	586-591	waste	quantity[32]|abstract[33]	new[32]|giv[33]	_	_
7-7	592-594	is	_	_	_	_
7-8	595-597	in	_	_	_	_
7-9	598-601	the	abstract[34]	new[34]	_	_
7-10	602-606	form	abstract[34]	new[34]	_	_
7-11	607-609	of	abstract[34]	new[34]	_	_
7-12	610-615	bones	abstract[34]|object	new[34]|new	_	_
7-13	616-619	and	abstract[34]	new[34]	_	_
7-14	620-625	skins	abstract[34]|object	new[34]|new	coref	8-9[40_0]
7-15	626-627	.	_	_	_	_

#Text=Gelatine can be derived from the processing of fish skins , solving the problem of waste disposal while producing a value-added product .
8-1	628-636	Gelatine	substance	new	coref	11-14
8-2	637-640	can	_	_	_	_
8-3	641-643	be	_	_	_	_
8-4	644-651	derived	_	_	_	_
8-5	652-656	from	_	_	_	_
8-6	657-660	the	abstract[38]	giv[38]	coref	13-16[79_38]
8-7	661-671	processing	abstract[38]	giv[38]	_	_
8-8	672-674	of	abstract[38]	giv[38]	_	_
8-9	675-679	fish	abstract[38]|animal|object[40]	giv[38]|giv|giv[40]	coref|coref	15-12|15-12
8-10	680-685	skins	abstract[38]|object[40]	giv[38]|giv[40]	_	_
8-11	686-687	,	_	_	_	_
8-12	688-695	solving	_	_	_	_
8-13	696-699	the	abstract[41]	new[41]	_	_
8-14	700-707	problem	abstract[41]	new[41]	_	_
8-15	708-710	of	abstract[41]	new[41]	_	_
8-16	711-716	waste	abstract[41]|abstract[42]	new[41]|new[42]	_	_
8-17	717-725	disposal	abstract[41]|abstract[42]	new[41]|new[42]	_	_
8-18	726-731	while	_	_	_	_
8-19	732-741	producing	_	_	_	_
8-20	742-743	a	object[43]	new[43]	coref	23-37[160_43]
8-21	744-755	value-added	object[43]	new[43]	_	_
8-22	756-763	product	object[43]	new[43]	_	_
8-23	764-765	.	_	_	_	_

#Text=Its fast growth rate , as well as good fodder usage cause carp ( Cyprinus carpio ) to be one of the most commonly-bred species in eastern Europe , as well as in Poland .
9-1	766-769	Its	quantity|abstract[46]	giv|new[46]	_	_
9-2	770-774	fast	abstract[46]	new[46]	_	_
9-3	775-781	growth	abstract|abstract[46]	new|new[46]	_	_
9-4	782-786	rate	abstract[46]	new[46]	_	_
9-5	787-788	,	_	_	_	_
9-6	789-791	as	_	_	_	_
9-7	792-796	well	_	_	_	_
9-8	797-799	as	_	_	_	_
9-9	800-804	good	abstract[49]	new[49]	appos	9-15[50_49]
9-10	805-811	fodder	object|abstract[49]	new|new[49]	_	_
9-11	812-817	usage	abstract|abstract[49]	new|new[49]	coref	17-1[99_0]
9-12	818-823	cause	abstract[49]	new[49]	_	_
9-13	824-828	carp	abstract[49]	new[49]	_	_
9-14	829-830	(	_	_	_	_
9-15	831-839	Cyprinus	abstract[50]	giv[50]	coref	10-4[0_50]
9-16	840-846	carpio	abstract[50]	giv[50]	_	_
9-17	847-848	)	_	_	_	_
9-18	849-851	to	_	_	_	_
9-19	852-854	be	_	_	_	_
9-20	855-858	one	abstract[51]	new[51]	_	_
9-21	859-861	of	abstract[51]	new[51]	_	_
9-22	862-865	the	abstract[51]|abstract[52]	new[51]|new[52]	coref	28-6[184_52]
9-23	866-870	most	abstract[51]|abstract[52]	new[51]|new[52]	_	_
9-24	871-884	commonly-bred	abstract[51]|abstract[52]	new[51]|new[52]	_	_
9-25	885-892	species	abstract[51]|abstract[52]	new[51]|new[52]	_	_
9-26	893-895	in	abstract[51]|abstract[52]	new[51]|new[52]	_	_
9-27	896-903	eastern	abstract[51]|abstract[52]|place[53]	new[51]|new[52]|new[53]	_	_
9-28	904-910	Europe	abstract[51]|abstract[52]|place[53]	new[51]|new[52]|new[53]	_	_
9-29	911-912	,	_	_	_	_
9-30	913-915	as	_	_	_	_
9-31	916-920	well	_	_	_	_
9-32	921-923	as	_	_	_	_
9-33	924-926	in	_	_	_	_
9-34	927-933	Poland	place	new	_	_
9-35	934-935	.	_	_	_	_

#Text=The annual European carp production totals approximately 4,328,083 tons .
10-1	936-939	The	abstract[56]	new[56]	_	_
10-2	940-946	annual	abstract[56]	new[56]	_	_
10-3	947-955	European	abstract[56]	new[56]	_	_
10-4	956-960	carp	abstract|abstract[56]	giv|new[56]	coref	11-12
10-5	961-971	production	abstract[56]	new[56]	_	_
10-6	972-978	totals	_	_	_	_
10-7	979-992	approximately	quantity[57]	new[57]	_	_
10-8	993-1002	4,328,083	quantity[57]	new[57]	_	_
10-9	1003-1007	tons	quantity[57]	new[57]	_	_
10-10	1008-1009	.	_	_	_	_

#Text=In our previous research , we demonstrated that protein hydrolysates from carp skin gelatine hydrolysate ( CSGH ) can be potential bioactive peptide sources .
11-1	1010-1012	In	_	_	_	_
11-2	1013-1016	our	person|abstract[59]	giv|new[59]	ana|coref|ana|coref	11-6|24-2[161_59]|11-6|24-2[161_59]
11-3	1017-1025	previous	abstract[59]	new[59]	_	_
11-4	1026-1034	research	abstract[59]	new[59]	_	_
11-5	1035-1036	,	_	_	_	_
11-6	1037-1039	we	person	giv	_	_
11-7	1040-1052	demonstrated	_	_	_	_
11-8	1053-1057	that	_	_	_	_
11-9	1058-1065	protein	substance|abstract[62]	new|new[62]	coref|coref|coref|coref	11-21[69_62]|15-13|11-21[69_62]|15-13
11-10	1066-1078	hydrolysates	abstract[62]	new[62]	_	_
11-11	1079-1083	from	abstract[62]	new[62]	_	_
11-12	1084-1088	carp	abstract[62]|abstract|object[66]	new[62]|giv|new[66]	appos|appos	11-17[0_66]|11-17[0_66]
11-13	1089-1093	skin	abstract[62]|object|object[66]	new[62]|new|new[66]	_	_
11-14	1094-1102	gelatine	abstract[62]|abstract|object[66]	new[62]|giv|new[66]	_	_
11-15	1103-1114	hydrolysate	abstract[62]|object[66]	new[62]|new[66]	_	_
11-16	1115-1116	(	_	_	_	_
11-17	1117-1121	CSGH	object	giv	_	_
11-18	1122-1123	)	_	_	_	_
11-19	1124-1127	can	_	_	_	_
11-20	1128-1130	be	_	_	_	_
11-21	1131-1140	potential	abstract[69]	giv[69]	coref	15-12[88_69]
11-22	1141-1150	bioactive	abstract[69]	giv[69]	_	_
11-23	1151-1158	peptide	place|abstract[69]	new|giv[69]	coref	16-8
11-24	1159-1166	sources	abstract[69]	giv[69]	_	_
11-25	1167-1168	.	_	_	_	_

#Text=Bioactive peptides consisting of 2 – 20 residues of amino acids are inactive within the sequences of parent proteins .
12-1	1169-1178	Bioactive	object[70]	new[70]	coref	14-1[81_70]
12-2	1179-1187	peptides	object[70]	new[70]	_	_
12-3	1188-1198	consisting	_	_	_	_
12-4	1199-1201	of	_	_	_	_
12-5	1202-1203	2	time[71]	new[71]	_	_
12-6	1204-1205	–	time[71]	new[71]	_	_
12-7	1206-1208	20	time[71]	new[71]	_	_
12-8	1209-1217	residues	time[71]	new[71]	_	_
12-9	1218-1220	of	time[71]	new[71]	_	_
12-10	1221-1226	amino	time[71]|substance[72]	new[71]|new[72]	ana	13-1[0_72]
12-11	1227-1232	acids	time[71]|substance[72]	new[71]|new[72]	_	_
12-12	1233-1236	are	_	_	_	_
12-13	1237-1245	inactive	_	_	_	_
12-14	1246-1252	within	_	_	_	_
12-15	1253-1256	the	abstract[73]	new[73]	_	_
12-16	1257-1266	sequences	abstract[73]	new[73]	_	_
12-17	1267-1269	of	abstract[73]	new[73]	_	_
12-18	1270-1276	parent	abstract[73]|substance[74]	new[73]|new[74]	coref	21-10[0_74]
12-19	1277-1285	proteins	abstract[73]|substance[74]	new[73]|new[74]	_	_
12-20	1286-1287	.	_	_	_	_

#Text=They can be released via enzymatic hydrolysis either at the time of digestion or during food processing .
13-1	1288-1292	They	substance	giv	_	_
13-2	1293-1296	can	_	_	_	_
13-3	1297-1299	be	_	_	_	_
13-4	1300-1308	released	_	_	_	_
13-5	1309-1312	via	_	_	_	_
13-6	1313-1322	enzymatic	substance[76]	new[76]	_	_
13-7	1323-1333	hydrolysis	substance[76]	new[76]	_	_
13-8	1334-1340	either	_	_	_	_
13-9	1341-1343	at	_	_	_	_
13-10	1344-1347	the	_	_	_	_
13-11	1348-1352	time	_	_	_	_
13-12	1353-1355	of	_	_	_	_
13-13	1356-1365	digestion	substance	new	_	_
13-14	1366-1368	or	_	_	_	_
13-15	1369-1375	during	_	_	_	_
13-16	1376-1380	food	substance|abstract[79]	new|giv[79]	coref|coref	15-7|15-7
13-17	1381-1391	processing	abstract[79]	giv[79]	_	_
13-18	1392-1393	.	_	_	_	_

#Text=Antioxidant peptides are among the most frequently-studied bioactive peptides .
14-1	1394-1405	Antioxidant	person|object[81]	giv|giv[81]	coref|coref|coref|coref	14-5[82_81]|15-16|14-5[82_81]|15-16
14-2	1406-1414	peptides	object[81]	giv[81]	_	_
14-3	1415-1418	are	_	_	_	_
14-4	1419-1424	among	_	_	_	_
14-5	1425-1428	the	object[82]	giv[82]	coref	27-1[178_82]
14-6	1429-1433	most	object[82]	giv[82]	_	_
14-7	1434-1452	frequently-studied	object[82]	giv[82]	_	_
14-8	1453-1462	bioactive	object[82]	giv[82]	_	_
14-9	1463-1471	peptides	object[82]	giv[82]	_	_
14-10	1472-1473	.	_	_	_	_

#Text=In particular , in the health food and pharmaceutical industry , fish protein hydrolysates with antioxidant properties have become a highly interesting and discussed subject .
15-1	1474-1476	In	_	_	_	_
15-2	1477-1487	particular	_	_	_	_
15-3	1488-1489	,	_	_	_	_
15-4	1490-1492	in	_	_	_	_
15-5	1493-1496	the	abstract[85]	new[85]	coref	34-42[246_85]
15-6	1497-1503	health	abstract|abstract[85]	new|new[85]	_	_
15-7	1504-1508	food	substance|abstract[85]	giv|new[85]	coref	22-19[148_0]
15-8	1509-1512	and	abstract[85]	new[85]	_	_
15-9	1513-1527	pharmaceutical	abstract[85]	new[85]	_	_
15-10	1528-1536	industry	abstract[85]	new[85]	_	_
15-11	1537-1538	,	_	_	_	_
15-12	1539-1543	fish	animal|abstract[88]	giv|giv[88]	coref|coref	28-10[186_88]|28-10[186_88]
15-13	1544-1551	protein	substance|abstract[88]	giv|giv[88]	coref	24-10
15-14	1552-1564	hydrolysates	abstract[88]	giv[88]	_	_
15-15	1565-1569	with	abstract[88]	giv[88]	_	_
15-16	1570-1581	antioxidant	abstract[88]|person|abstract[90]	giv[88]|giv|giv[90]	coref|coref	26-10[175_90]|26-10[175_90]
15-17	1582-1592	properties	abstract[88]|abstract[90]	giv[88]|giv[90]	_	_
15-18	1593-1597	have	_	_	_	_
15-19	1598-1604	become	_	_	_	_
15-20	1605-1606	a	_	_	_	_
15-21	1607-1613	highly	_	_	_	_
15-22	1614-1625	interesting	_	_	_	_
15-23	1626-1629	and	_	_	_	_
15-24	1630-1639	discussed	_	_	_	_
15-25	1640-1647	subject	_	_	_	_
15-26	1648-1649	.	_	_	_	_

#Text=There can be a reduction in bioactive peptide activity due to susceptibility to proteolytic degradation or undesirable interactions with other compounds .
16-1	1650-1655	There	_	_	_	_
16-2	1656-1659	can	_	_	_	_
16-3	1660-1662	be	_	_	_	_
16-4	1663-1664	a	abstract[91]	new[91]	_	_
16-5	1665-1674	reduction	abstract[91]	new[91]	_	_
16-6	1675-1677	in	abstract[91]	new[91]	_	_
16-7	1678-1687	bioactive	abstract[91]|abstract[93]	new[91]|new[93]	_	_
16-8	1688-1695	peptide	abstract[91]|substance|abstract[93]	new[91]|giv|new[93]	_	_
16-9	1696-1704	activity	abstract[91]|abstract[93]	new[91]|new[93]	_	_
16-10	1705-1708	due	_	_	_	_
16-11	1709-1711	to	_	_	_	_
16-12	1712-1726	susceptibility	abstract[94]	new[94]	_	_
16-13	1727-1729	to	abstract[94]	new[94]	_	_
16-14	1730-1741	proteolytic	abstract[94]|abstract[95]	new[94]|new[95]	coref	19-17[0_95]
16-15	1742-1753	degradation	abstract[94]|abstract[95]	new[94]|new[95]	_	_
16-16	1754-1756	or	abstract[94]	new[94]	_	_
16-17	1757-1768	undesirable	abstract[94]|abstract[96]	new[94]|new[96]	coref	36-1[254_96]
16-18	1769-1781	interactions	abstract[94]|abstract[96]	new[94]|new[96]	_	_
16-19	1782-1786	with	abstract[94]|abstract[96]	new[94]|new[96]	_	_
16-20	1787-1792	other	abstract[94]|abstract[96]|substance[97]	new[94]|new[96]|new[97]	coref	26-13[176_97]
16-21	1793-1802	compounds	abstract[94]|abstract[96]|substance[97]	new[94]|new[96]|new[97]	_	_
16-22	1803-1804	.	_	_	_	_

#Text=Encapsulation usage is a highly significant factor in the protection of these biomolecules , consequently providing greater therapeutic efficacy .
17-1	1805-1818	Encapsulation	abstract|abstract[99]	new|giv[99]	coref|coref|coref|coref	17-4[100_99]|18-1|17-4[100_99]|18-1
17-2	1819-1824	usage	abstract[99]	giv[99]	_	_
17-3	1825-1827	is	_	_	_	_
17-4	1828-1829	a	abstract[100]	giv[100]	_	_
17-5	1830-1836	highly	abstract[100]	giv[100]	_	_
17-6	1837-1848	significant	abstract[100]	giv[100]	_	_
17-7	1849-1855	factor	abstract[100]	giv[100]	_	_
17-8	1856-1858	in	abstract[100]	giv[100]	_	_
17-9	1859-1862	the	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
17-10	1863-1873	protection	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
17-11	1874-1876	of	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
17-12	1877-1882	these	abstract[100]|abstract[101]|substance[102]	giv[100]|new[101]|new[102]	_	_
17-13	1883-1895	biomolecules	abstract[100]|abstract[101]|substance[102]	giv[100]|new[101]|new[102]	_	_
17-14	1896-1897	,	_	_	_	_
17-15	1898-1910	consequently	_	_	_	_
17-16	1911-1920	providing	_	_	_	_
17-17	1921-1928	greater	abstract[103]	new[103]	_	_
17-18	1929-1940	therapeutic	abstract[103]	new[103]	_	_
17-19	1941-1949	efficacy	abstract[103]	new[103]	_	_
17-20	1950-1951	.	_	_	_	_

#Text=Encapsulation may also permit the development of the delivery system through the improvement of stability , causing an increase in residence time regarding circulation , while at the same time causing a significant decrease in toxicity .
18-1	1952-1965	Encapsulation	abstract	giv	_	_
18-2	1966-1969	may	_	_	_	_
18-3	1970-1974	also	_	_	_	_
18-4	1975-1981	permit	_	_	_	_
18-5	1982-1985	the	abstract[105]	new[105]	_	_
18-6	1986-1997	development	abstract[105]	new[105]	_	_
18-7	1998-2000	of	abstract[105]	new[105]	_	_
18-8	2001-2004	the	abstract[105]|abstract[107]	new[105]|new[107]	_	_
18-9	2005-2013	delivery	abstract[105]|abstract|abstract[107]	new[105]|new|new[107]	coref	20-5
18-10	2014-2020	system	abstract[105]|abstract[107]	new[105]|new[107]	_	_
18-11	2021-2028	through	abstract[105]|abstract[107]	new[105]|new[107]	_	_
18-12	2029-2032	the	abstract[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
18-13	2033-2044	improvement	abstract[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
18-14	2045-2047	of	abstract[105]|abstract[107]|abstract[108]	new[105]|new[107]|new[108]	_	_
18-15	2048-2057	stability	abstract[105]|abstract[107]|abstract[108]|abstract	new[105]|new[107]|new[108]|new	_	_
18-16	2058-2059	,	_	_	_	_
18-17	2060-2067	causing	_	_	_	_
18-18	2068-2070	an	abstract[110]	new[110]	_	_
18-19	2071-2079	increase	abstract[110]	new[110]	_	_
18-20	2080-2082	in	abstract[110]	new[110]	_	_
18-21	2083-2092	residence	abstract[110]|place|time[112]	new[110]|new|new[112]	coref|coref	18-28[114_112]|18-28[114_112]
18-22	2093-2097	time	abstract[110]|time[112]	new[110]|new[112]	_	_
18-23	2098-2107	regarding	_	_	_	_
18-24	2108-2119	circulation	abstract	new	_	_
18-25	2120-2121	,	_	_	_	_
18-26	2122-2127	while	_	_	_	_
18-27	2128-2130	at	_	_	_	_
18-28	2131-2134	the	time[114]	giv[114]	_	_
18-29	2135-2139	same	time[114]	giv[114]	_	_
18-30	2140-2144	time	time[114]	giv[114]	_	_
18-31	2145-2152	causing	_	_	_	_
18-32	2153-2154	a	abstract[115]	new[115]	_	_
18-33	2155-2166	significant	abstract[115]	new[115]	_	_
18-34	2167-2175	decrease	abstract[115]	new[115]	_	_
18-35	2176-2178	in	abstract[115]	new[115]	_	_
18-36	2179-2187	toxicity	abstract[115]|abstract	new[115]|new	_	_
18-37	2188-2189	.	_	_	_	_

#Text=The encapsulation of bioactive ingredients within colloidal particles is an influential means of protecting them from degradation .
19-1	2190-2193	The	abstract[117]	new[117]	coref	19-10[121_117]
19-2	2194-2207	encapsulation	abstract[117]	new[117]	_	_
19-3	2208-2210	of	abstract[117]	new[117]	_	_
19-4	2211-2220	bioactive	abstract[117]|substance[118]	new[117]|new[118]	_	_
19-5	2221-2232	ingredients	abstract[117]|substance[118]	new[117]|new[118]	_	_
19-6	2233-2239	within	abstract[117]|substance[118]	new[117]|new[118]	_	_
19-7	2240-2249	colloidal	abstract[117]|substance[118]|object|object[120]	new[117]|new[118]|new|new[120]	ana|ana	19-15[0_120]|19-15[0_120]
19-8	2250-2259	particles	abstract[117]|substance[118]|object[120]	new[117]|new[118]|new[120]	_	_
19-9	2260-2262	is	_	_	_	_
19-10	2263-2265	an	abstract[121]	giv[121]	coref	30-15[0_121]
19-11	2266-2277	influential	abstract[121]	giv[121]	_	_
19-12	2278-2283	means	abstract[121]	giv[121]	_	_
19-13	2284-2286	of	_	_	_	_
19-14	2287-2297	protecting	_	_	_	_
19-15	2298-2302	them	object	giv	_	_
19-16	2303-2307	from	_	_	_	_
19-17	2308-2319	degradation	abstract	giv	ana	20-34
19-18	2320-2321	.	_	_	_	_

#Text=Different types of colloidal delivery systems have been developed , for example emulsions , nanoemulsions , microemulsions , liposomes , solid lipid nanoparticles , hydrogel beads , and biopolymer nanoparticles , each with its own advantages and disadvantages .
20-1	2322-2331	Different	abstract[124]	new[124]	_	_
20-2	2332-2337	types	abstract[124]	new[124]	_	_
20-3	2338-2340	of	abstract[124]	new[124]	_	_
20-4	2341-2350	colloidal	abstract[124]|abstract[126]	new[124]|new[126]	_	_
20-5	2351-2359	delivery	abstract[124]|abstract|abstract[126]	new[124]|giv|new[126]	coref	32-6
20-6	2360-2367	systems	abstract[124]|abstract[126]	new[124]|new[126]	_	_
20-7	2368-2372	have	_	_	_	_
20-8	2373-2377	been	_	_	_	_
20-9	2378-2387	developed	_	_	_	_
20-10	2388-2389	,	_	_	_	_
20-11	2390-2393	for	_	_	_	_
20-12	2394-2401	example	object[127]	new[127]	_	_
20-13	2402-2411	emulsions	object[127]	new[127]	_	_
20-14	2412-2413	,	_	_	_	_
20-15	2414-2427	nanoemulsions	object	new	_	_
20-16	2428-2429	,	_	_	_	_
20-17	2430-2444	microemulsions	object	new	_	_
20-18	2445-2446	,	_	_	_	_
20-19	2447-2456	liposomes	object	new	_	_
20-20	2457-2458	,	_	_	_	_
20-21	2459-2464	solid	object[132]	new[132]	_	_
20-22	2465-2470	lipid	person|object[132]	new|new[132]	_	_
20-23	2471-2484	nanoparticles	object[132]	new[132]	_	_
20-24	2485-2486	,	_	_	_	_
20-25	2487-2495	hydrogel	substance|object[134]	new|new[134]	_	_
20-26	2496-2501	beads	object[134]	new[134]	_	_
20-27	2502-2503	,	_	_	_	_
20-28	2504-2507	and	_	_	_	_
20-29	2508-2518	biopolymer	person|object[136]	new|new[136]	coref|coref	37-12|37-12
20-30	2519-2532	nanoparticles	object[136]	new[136]	_	_
20-31	2533-2534	,	_	_	_	_
20-32	2535-2539	each	_	_	_	_
20-33	2540-2544	with	_	_	_	_
20-34	2545-2548	its	abstract|abstract[138]	giv|new[138]	_	_
20-35	2549-2552	own	abstract[138]	new[138]	_	_
20-36	2553-2563	advantages	abstract[138]	new[138]	_	_
20-37	2564-2567	and	_	_	_	_
20-38	2568-2581	disadvantages	abstract	new	_	_
20-39	2582-2583	.	_	_	_	_

#Text=Edible coating materials are usually composed of polysaccharides and proteins .
21-1	2584-2590	Edible	substance[141]	new[141]	coref	22-1[144_141]
21-2	2591-2598	coating	object|substance[141]	new|new[141]	_	_
21-3	2599-2608	materials	substance[141]	new[141]	_	_
21-4	2609-2612	are	_	_	_	_
21-5	2613-2620	usually	_	_	_	_
21-6	2621-2629	composed	_	_	_	_
21-7	2630-2632	of	_	_	_	_
21-8	2633-2648	polysaccharides	substance	new	coref	32-1
21-9	2649-2652	and	_	_	_	_
21-10	2653-2661	proteins	substance	giv	coref	35-9[249_0]
21-11	2662-2663	.	_	_	_	_

#Text=These materials could be used not only in the form of capsules , but also as films covering the food .
22-1	2664-2669	These	substance[144]	giv[144]	coref	36-13[258_144]
22-2	2670-2679	materials	substance[144]	giv[144]	_	_
22-3	2680-2685	could	_	_	_	_
22-4	2686-2688	be	_	_	_	_
22-5	2689-2693	used	_	_	_	_
22-6	2694-2697	not	_	_	_	_
22-7	2698-2702	only	abstract[145]	new[145]	_	_
22-8	2703-2705	in	abstract[145]	new[145]	_	_
22-9	2706-2709	the	abstract[145]	new[145]	_	_
22-10	2710-2714	form	abstract[145]	new[145]	_	_
22-11	2715-2717	of	abstract[145]	new[145]	_	_
22-12	2718-2726	capsules	abstract[145]|object	new[145]|new	_	_
22-13	2727-2728	,	_	_	_	_
22-14	2729-2732	but	_	_	_	_
22-15	2733-2737	also	_	_	_	_
22-16	2738-2740	as	_	_	_	_
22-17	2741-2746	films	object	new	coref	23-1[149_0]
22-18	2747-2755	covering	_	_	_	_
22-19	2756-2759	the	substance[148]	giv[148]	coref	23-10[0_148]
22-20	2760-2764	food	substance[148]	giv[148]	_	_
22-21	2765-2766	.	_	_	_	_

#Text=Edible films and coatings often containing bioactive agents or food additives like nutrients are gaining relevance as potential tools to reduce the deleterious effects of the incidence of microorganisms or to improve the nutritional value of a product .
23-1	2767-2773	Edible	object[149]	giv[149]	coref	24-9[164_149]
23-2	2774-2779	films	object[149]	giv[149]	_	_
23-3	2780-2783	and	object[149]	giv[149]	_	_
23-4	2784-2792	coatings	object[149]|object	giv[149]|new	_	_
23-5	2793-2798	often	_	_	_	_
23-6	2799-2809	containing	_	_	_	_
23-7	2810-2819	bioactive	substance[151]	new[151]	_	_
23-8	2820-2826	agents	substance[151]	new[151]	_	_
23-9	2827-2829	or	_	_	_	_
23-10	2830-2834	food	substance|substance[153]	giv|new[153]	coref|coref	27-6|27-6
23-11	2835-2844	additives	substance[153]	new[153]	_	_
23-12	2845-2849	like	substance[153]	new[153]	_	_
23-13	2850-2859	nutrients	substance[153]|substance	new[153]|giv	_	_
23-14	2860-2863	are	_	_	_	_
23-15	2864-2871	gaining	_	_	_	_
23-16	2872-2881	relevance	abstract	new	_	_
23-17	2882-2884	as	_	_	_	_
23-18	2885-2894	potential	_	_	_	_
23-19	2895-2900	tools	_	_	_	_
23-20	2901-2903	to	_	_	_	_
23-21	2904-2910	reduce	_	_	_	_
23-22	2911-2914	the	abstract[156]	giv[156]	_	_
23-23	2915-2926	deleterious	abstract[156]	giv[156]	_	_
23-24	2927-2934	effects	abstract[156]	giv[156]	_	_
23-25	2935-2937	of	abstract[156]	giv[156]	_	_
23-26	2938-2941	the	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
23-27	2942-2951	incidence	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
23-28	2952-2954	of	abstract[156]|abstract[157]	giv[156]|new[157]	_	_
23-29	2955-2969	microorganisms	abstract[156]|abstract[157]|abstract	giv[156]|new[157]|new	_	_
23-30	2970-2972	or	_	_	_	_
23-31	2973-2975	to	_	_	_	_
23-32	2976-2983	improve	_	_	_	_
23-33	2984-2987	the	abstract[159]	new[159]	_	_
23-34	2988-2999	nutritional	abstract[159]	new[159]	_	_
23-35	3000-3005	value	abstract[159]	new[159]	_	_
23-36	3006-3008	of	abstract[159]	new[159]	_	_
23-37	3009-3010	a	abstract[159]|object[160]	new[159]|giv[160]	_	_
23-38	3011-3018	product	abstract[159]|object[160]	new[159]|giv[160]	_	_
23-39	3019-3020	.	_	_	_	_

#Text=In the research by Sapper et al. , polysaccharide protein films with the addition of thyme essential oil were obtained , which has a strong in vitro fungicidal effect .
24-1	3021-3023	In	_	_	_	_
24-2	3024-3027	the	abstract[161]	giv[161]	_	_
24-3	3028-3036	research	abstract[161]	giv[161]	_	_
24-4	3037-3039	by	abstract[161]	giv[161]	_	_
24-5	3040-3046	Sapper	abstract[161]|person	giv[161]|new	_	_
24-6	3047-3049	et	abstract[161]	giv[161]	_	_
24-7	3050-3053	al.	abstract[161]	giv[161]	_	_
24-8	3054-3055	,	_	_	_	_
24-9	3056-3070	polysaccharide	object[164]	giv[164]	coref	37-10[261_164]
24-10	3071-3078	protein	substance|object[164]	giv|giv[164]	coref	28-11
24-11	3079-3084	films	object[164]	giv[164]	_	_
24-12	3085-3089	with	object[164]	giv[164]	_	_
24-13	3090-3093	the	object[164]|abstract[165]	giv[164]|new[165]	_	_
24-14	3094-3102	addition	object[164]|abstract[165]	giv[164]|new[165]	_	_
24-15	3103-3105	of	object[164]|abstract[165]	giv[164]|new[165]	_	_
24-16	3106-3111	thyme	object[164]|abstract[165]|abstract|substance[167]	giv[164]|new[165]|new|new[167]	_	_
24-17	3112-3121	essential	object[164]|abstract[165]|substance[167]	giv[164]|new[165]|new[167]	_	_
24-18	3122-3125	oil	object[164]|abstract[165]|substance[167]	giv[164]|new[165]|new[167]	_	_
24-19	3126-3130	were	_	_	_	_
24-20	3131-3139	obtained	_	_	_	_
24-21	3140-3141	,	_	_	_	_
24-22	3142-3147	which	_	_	_	_
24-23	3148-3151	has	_	_	_	_
24-24	3152-3153	a	_	_	_	_
24-25	3154-3160	strong	_	_	_	_
24-26	3161-3163	in	_	_	_	_
24-27	3164-3169	vitro	abstract[168]	new[168]	coref	25-9[170_168]
24-28	3170-3180	fungicidal	abstract[168]	new[168]	_	_
24-29	3181-3187	effect	abstract[168]	new[168]	_	_
24-30	3188-3189	.	_	_	_	_

#Text=However , in vivo studies did not confirm the inhibitory effect on the surface of apples .
25-1	3190-3197	However	_	_	_	_
25-2	3198-3199	,	_	_	_	_
25-3	3200-3202	in	_	_	_	_
25-4	3203-3207	vivo	event[169]	new[169]	coref	29-1[187_169]
25-5	3208-3215	studies	event[169]	new[169]	_	_
25-6	3216-3219	did	_	_	_	_
25-7	3220-3223	not	_	_	_	_
25-8	3224-3231	confirm	_	_	_	_
25-9	3232-3235	the	abstract[170]	giv[170]	_	_
25-10	3236-3246	inhibitory	abstract[170]	giv[170]	_	_
25-11	3247-3253	effect	abstract[170]	giv[170]	_	_
25-12	3254-3256	on	abstract[170]	giv[170]	_	_
25-13	3257-3260	the	abstract[170]|place[171]	giv[170]|new[171]	_	_
25-14	3261-3268	surface	abstract[170]|place[171]	giv[170]|new[171]	_	_
25-15	3269-3271	of	abstract[170]|place[171]	giv[170]|new[171]	_	_
25-16	3272-3278	apples	abstract[170]|place[171]|plant	giv[170]|new[171]|new	_	_
25-17	3279-3280	.	_	_	_	_

#Text=Furthermore , other data from the literature indicate that the properties of biologically-active compounds tested in vitro are not always confirmed in vivo .
26-1	3281-3292	Furthermore	_	_	_	_
26-2	3293-3294	,	_	_	_	_
26-3	3295-3300	other	abstract[173]	new[173]	_	_
26-4	3301-3305	data	abstract[173]	new[173]	_	_
26-5	3306-3310	from	abstract[173]	new[173]	_	_
26-6	3311-3314	the	abstract[173]|abstract[174]	new[173]|new[174]	coref	30-8[197_174]
26-7	3315-3325	literature	abstract[173]|abstract[174]	new[173]|new[174]	_	_
26-8	3326-3334	indicate	_	_	_	_
26-9	3335-3339	that	_	_	_	_
26-10	3340-3343	the	abstract[175]	giv[175]	_	_
26-11	3344-3354	properties	abstract[175]	giv[175]	_	_
26-12	3355-3357	of	abstract[175]	giv[175]	_	_
26-13	3358-3377	biologically-active	abstract[175]|substance[176]	giv[175]|giv[176]	coref	27-5[180_176]
26-14	3378-3387	compounds	abstract[175]|substance[176]	giv[175]|giv[176]	_	_
26-15	3388-3394	tested	_	_	_	_
26-16	3395-3397	in	_	_	_	_
26-17	3398-3403	vitro	_	_	_	_
26-18	3404-3407	are	_	_	_	_
26-19	3408-3411	not	_	_	_	_
26-20	3412-3418	always	_	_	_	_
26-21	3419-3428	confirmed	_	_	_	_
26-22	3429-3431	in	_	_	_	_
26-23	3432-3436	vivo	_	_	_	_
26-24	3437-3438	.	_	_	_	_

#Text=Bioactive peptides differ from other food bioactive compounds like vitamins or polyphenols .
27-1	3439-3448	Bioactive	abstract|object[178]	new|giv[178]	coref|coref	29-4[188_178]|29-4[188_178]
27-2	3449-3457	peptides	object[178]	giv[178]	_	_
27-3	3458-3464	differ	_	_	_	_
27-4	3465-3469	from	_	_	_	_
27-5	3470-3475	other	substance[180]	giv[180]	_	_
27-6	3476-3480	food	substance|substance[180]	giv|giv[180]	coref	34-43
27-7	3481-3490	bioactive	substance[180]	giv[180]	_	_
27-8	3491-3500	compounds	substance[180]	giv[180]	_	_
27-9	3501-3505	like	substance[180]	giv[180]	_	_
27-10	3506-3514	vitamins	substance[180]|substance	giv[180]|new	_	_
27-11	3515-3517	or	substance[180]	giv[180]	_	_
27-12	3518-3529	polyphenols	substance[180]|substance	giv[180]|new	_	_
27-13	3530-3531	.	_	_	_	_

#Text=There is slight heterogeneity regarding the chemical species in the protein hydrolysates .
28-1	3532-3537	There	_	_	_	_
28-2	3538-3540	is	_	_	_	_
28-3	3541-3547	slight	abstract[183]	new[183]	_	_
28-4	3548-3561	heterogeneity	abstract[183]	new[183]	_	_
28-5	3562-3571	regarding	_	_	_	_
28-6	3572-3575	the	abstract[184]	giv[184]	_	_
28-7	3576-3584	chemical	abstract[184]	giv[184]	_	_
28-8	3585-3592	species	abstract[184]	giv[184]	_	_
28-9	3593-3595	in	abstract[184]	giv[184]	_	_
28-10	3596-3599	the	abstract[184]|abstract[186]	giv[184]|giv[186]	_	_
28-11	3600-3607	protein	abstract[184]|substance|abstract[186]	giv[184]|giv|giv[186]	coref	29-12
28-12	3608-3620	hydrolysates	abstract[184]|abstract[186]	giv[184]|giv[186]	_	_
28-13	3621-3622	.	_	_	_	_

#Text=Most studies on bioactive peptides focus on finding new bioactivity and protein precursors , while limited attention is paid to their biostability or bioavailability .
29-1	3623-3627	Most	event[187]	giv[187]	coref	31-9[203_187]
29-2	3628-3635	studies	event[187]	giv[187]	_	_
29-3	3636-3638	on	event[187]	giv[187]	_	_
29-4	3639-3648	bioactive	event[187]|object[188]	giv[187]|giv[188]	coref	30-17[200_188]
29-5	3649-3657	peptides	event[187]|object[188]	giv[187]|giv[188]	_	_
29-6	3658-3663	focus	_	_	_	_
29-7	3664-3666	on	_	_	_	_
29-8	3667-3674	finding	_	_	_	_
29-9	3675-3678	new	abstract[189]	new[189]	coref	31-21[0_189]
29-10	3679-3690	bioactivity	abstract[189]	new[189]	_	_
29-11	3691-3694	and	_	_	_	_
29-12	3695-3702	protein	substance|substance[191]	giv|new[191]	ana|ana	29-21[0_191]|29-21[0_191]
29-13	3703-3713	precursors	substance[191]	new[191]	_	_
29-14	3714-3715	,	_	_	_	_
29-15	3716-3721	while	_	_	_	_
29-16	3722-3729	limited	abstract[192]	new[192]	_	_
29-17	3730-3739	attention	abstract[192]	new[192]	_	_
29-18	3740-3742	is	_	_	_	_
29-19	3743-3747	paid	_	_	_	_
29-20	3748-3750	to	_	_	_	_
29-21	3751-3756	their	substance|abstract[194]	giv|new[194]	_	_
29-22	3757-3769	biostability	abstract[194]	new[194]	_	_
29-23	3770-3772	or	_	_	_	_
29-24	3773-3788	bioavailability	substance	new	_	_
29-25	3789-3790	.	_	_	_	_

#Text=Presently , there is a gap in the literature illustrating the various aspects of encapsulation concerning food-protein-derived bioactive peptides .
30-1	3791-3800	Presently	_	_	_	_
30-2	3801-3802	,	_	_	_	_
30-3	3803-3808	there	_	_	_	_
30-4	3809-3811	is	_	_	_	_
30-5	3812-3813	a	abstract[196]	new[196]	_	_
30-6	3814-3817	gap	abstract[196]	new[196]	_	_
30-7	3818-3820	in	abstract[196]	new[196]	_	_
30-8	3821-3824	the	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
30-9	3825-3835	literature	abstract[196]|abstract[197]	new[196]|giv[197]	_	_
30-10	3836-3848	illustrating	_	_	_	_
30-11	3849-3852	the	abstract[198]	new[198]	_	_
30-12	3853-3860	various	abstract[198]	new[198]	_	_
30-13	3861-3868	aspects	abstract[198]	new[198]	_	_
30-14	3869-3871	of	abstract[198]	new[198]	_	_
30-15	3872-3885	encapsulation	abstract[198]|abstract	new[198]|giv	coref	31-19[207_0]
30-16	3886-3896	concerning	_	_	_	_
30-17	3897-3917	food-protein-derived	object[200]	giv[200]	_	_
30-18	3918-3927	bioactive	object[200]	giv[200]	_	_
30-19	3928-3936	peptides	object[200]	giv[200]	_	_
30-20	3937-3938	.	_	_	_	_

#Text=Moreover , there is a need for in vivo studies applying animal models to confirm the success of encapsulation in bioactivity retention following the oral consumption of these products .
31-1	3939-3947	Moreover	_	_	_	_
31-2	3948-3949	,	_	_	_	_
31-3	3950-3955	there	_	_	_	_
31-4	3956-3958	is	_	_	_	_
31-5	3959-3960	a	abstract[201]	new[201]	_	_
31-6	3961-3965	need	abstract[201]	new[201]	_	_
31-7	3966-3969	for	abstract[201]	new[201]	_	_
31-8	3970-3972	in	abstract[201]	new[201]	_	_
31-9	3973-3977	vivo	abstract[201]|abstract|event[203]	new[201]|new|giv[203]	_	_
31-10	3978-3985	studies	abstract[201]|event[203]	new[201]|giv[203]	_	_
31-11	3986-3994	applying	_	_	_	_
31-12	3995-4001	animal	person|abstract[205]	new|new[205]	ana|ana	32-11[0_205]|32-11[0_205]
31-13	4002-4008	models	abstract[205]	new[205]	_	_
31-14	4009-4011	to	_	_	_	_
31-15	4012-4019	confirm	_	_	_	_
31-16	4020-4023	the	abstract[206]	new[206]	_	_
31-17	4024-4031	success	abstract[206]	new[206]	_	_
31-18	4032-4034	of	abstract[206]	new[206]	_	_
31-19	4035-4048	encapsulation	abstract[206]|abstract[207]	new[206]|giv[207]	coref	35-17[250_207]
31-20	4049-4051	in	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
31-21	4052-4063	bioactivity	abstract[206]|abstract[207]|abstract|abstract[209]	new[206]|giv[207]|giv|new[209]	_	_
31-22	4064-4073	retention	abstract[206]|abstract[207]|abstract[209]	new[206]|giv[207]|new[209]	_	_
31-23	4074-4083	following	_	_	_	_
31-24	4084-4087	the	abstract[210]	new[210]	_	_
31-25	4088-4092	oral	abstract[210]	new[210]	_	_
31-26	4093-4104	consumption	abstract[210]	new[210]	_	_
31-27	4105-4107	of	abstract[210]	new[210]	_	_
31-28	4108-4113	these	abstract[210]|substance[211]	new[210]|new[211]	_	_
31-29	4114-4122	products	abstract[210]|substance[211]	new[210]|new[211]	_	_
31-30	4123-4124	.	_	_	_	_

#Text=Polysaccharides are generally ideal as delivery agents in microcapsules as they are structurally stable , ample in nature , and inexpensive .
32-1	4125-4140	Polysaccharides	object	giv	coref	33-1[217_0]
32-2	4141-4144	are	_	_	_	_
32-3	4145-4154	generally	_	_	_	_
32-4	4155-4160	ideal	_	_	_	_
32-5	4161-4163	as	_	_	_	_
32-6	4164-4172	delivery	abstract	giv	_	_
32-7	4173-4179	agents	_	_	_	_
32-8	4180-4182	in	_	_	_	_
32-9	4183-4196	microcapsules	object	new	_	_
32-10	4197-4199	as	_	_	_	_
32-11	4200-4204	they	abstract	giv	_	_
32-12	4205-4208	are	_	_	_	_
32-13	4209-4221	structurally	_	_	_	_
32-14	4222-4228	stable	_	_	_	_
32-15	4229-4230	,	_	_	_	_
32-16	4231-4236	ample	_	_	_	_
32-17	4237-4239	in	_	_	_	_
32-18	4240-4246	nature	abstract	new	_	_
32-19	4247-4248	,	_	_	_	_
32-20	4249-4252	and	_	_	_	_
32-21	4253-4264	inexpensive	_	_	_	_
32-22	4265-4266	.	_	_	_	_

#Text=Polysaccharides with reactive functional groups ( carboxyl ( COOH ) ) , hydroxyl ( OH ) , amide ( NH2 ) , and sulphate groups ( SO4H ) ) are good candidates as carrier matrices . Furcellaran ( FUR ) is structurally connected with the algal polysaccharide κ carrageenan ; however , there is a major structural difference .
33-1	4267-4282	Polysaccharides	person[217]	giv[217]	coref	33-31[226_217]
33-2	4283-4287	with	person[217]	giv[217]	_	_
33-3	4288-4296	reactive	person[217]|person[218]	giv[217]|new[218]	_	_
33-4	4297-4307	functional	person[217]|person[218]	giv[217]|new[218]	_	_
33-5	4308-4314	groups	person[217]|person[218]	giv[217]|new[218]	_	_
33-6	4315-4316	(	_	_	_	_
33-7	4317-4325	carboxyl	substance	new	_	_
33-8	4326-4327	(	_	_	_	_
33-9	4328-4332	COOH	abstract	new	_	_
33-10	4333-4334	)	_	_	_	_
33-11	4335-4336	)	_	_	_	_
33-12	4337-4338	,	_	_	_	_
33-13	4339-4347	hydroxyl	abstract	new	_	_
33-14	4348-4349	(	_	_	_	_
33-15	4350-4352	OH	_	_	_	_
33-16	4353-4354	)	_	_	_	_
33-17	4355-4356	,	_	_	_	_
33-18	4357-4362	amide	abstract	new	appos	33-20
33-19	4363-4364	(	_	_	_	_
33-20	4365-4368	NH2	abstract	giv	_	_
33-21	4369-4370	)	_	_	_	_
33-22	4371-4372	,	_	_	_	_
33-23	4373-4376	and	_	_	_	_
33-24	4377-4385	sulphate	person[224]	new[224]	_	_
33-25	4386-4392	groups	person[224]	new[224]	_	_
33-26	4393-4394	(	_	_	_	_
33-27	4395-4399	SO4H	substance	new	_	_
33-28	4400-4401	)	_	_	_	_
33-29	4402-4403	)	_	_	_	_
33-30	4404-4407	are	_	_	_	_
33-31	4408-4412	good	person[226]	giv[226]	coref	36-6[0_226]
33-32	4413-4423	candidates	person[226]	giv[226]	_	_
33-33	4424-4426	as	person[226]	giv[226]	_	_
33-34	4427-4434	carrier	person[226]	giv[226]	_	_
33-35	4435-4443	matrices	person[226]	giv[226]	_	_
33-36	4444-4445	.	_	_	_	_
33-37	4446-4457	Furcellaran	substance	new	coref	34-1
33-38	4458-4459	(	_	_	_	_
33-39	4460-4463	FUR	object	new	_	_
33-40	4464-4465	)	_	_	_	_
33-41	4466-4468	is	_	_	_	_
33-42	4469-4481	structurally	_	_	_	_
33-43	4482-4491	connected	_	_	_	_
33-44	4492-4496	with	_	_	_	_
33-45	4497-4500	the	abstract[231]	new[231]	_	_
33-46	4501-4506	algal	abstract[231]	new[231]	_	_
33-47	4507-4521	polysaccharide	substance|abstract[231]	new|new[231]	_	_
33-48	4522-4523	κ	abstract|abstract[231]	new|new[231]	_	_
33-49	4524-4535	carrageenan	abstract[231]	new[231]	_	_
33-50	4536-4537	;	_	_	_	_
33-51	4538-4545	however	_	_	_	_
33-52	4546-4547	,	_	_	_	_
33-53	4548-4553	there	_	_	_	_
33-54	4554-4556	is	_	_	_	_
33-55	4557-4558	a	abstract[232]	new[232]	_	_
33-56	4559-4564	major	abstract[232]	new[232]	_	_
33-57	4565-4575	structural	abstract[232]	new[232]	_	_
33-58	4576-4586	difference	abstract[232]	new[232]	_	_
33-59	4587-4588	.	_	_	_	_

#Text=Furcellaran , which has units consisting of a fragment of ( 1 – 3 ) β-D-galactopyranose with a sulphate group at C-4 and ( 1 – 4 ) -3 , 6-anhydro-α-D-galactopyranose , is used as a gelling and stabilizing agent in the food industry .
34-1	4589-4600	Furcellaran	substance	giv	coref	35-4
34-2	4601-4602	,	_	_	_	_
34-3	4603-4608	which	_	_	_	_
34-4	4609-4612	has	_	_	_	_
34-5	4613-4618	units	object	new	_	_
34-6	4619-4629	consisting	_	_	_	_
34-7	4630-4632	of	_	_	_	_
34-8	4633-4634	a	abstract[235]	new[235]	_	_
34-9	4635-4643	fragment	abstract[235]	new[235]	_	_
34-10	4644-4646	of	_	_	_	_
34-11	4647-4648	(	_	_	_	_
34-12	4649-4650	1	time[236]	giv[236]	_	_
34-13	4651-4652	–	time[236]	giv[236]	_	_
34-14	4653-4654	3	time[236]|quantity	giv[236]|new	_	_
34-15	4655-4656	)	_	_	_	_
34-16	4657-4676	β-D-galactopyranose	substance[238]	new[238]	_	_
34-17	4677-4681	with	substance[238]	new[238]	_	_
34-18	4682-4683	a	substance[238]|person[240]	new[238]|new[240]	_	_
34-19	4684-4692	sulphate	substance[238]|abstract|person[240]	new[238]|new|new[240]	_	_
34-20	4693-4698	group	substance[238]|person[240]	new[238]|new[240]	_	_
34-21	4699-4701	at	substance[238]|person[240]	new[238]|new[240]	_	_
34-22	4702-4705	C-4	substance[238]|person[240]|abstract	new[238]|new[240]|new	_	_
34-23	4706-4709	and	substance[238]|person[240]	new[238]|new[240]	_	_
34-24	4710-4711	(	substance[238]|person[240]	new[238]|new[240]	_	_
34-25	4712-4713	1	substance[238]|person[240]	new[238]|new[240]	_	_
34-26	4714-4715	–	substance[238]|person[240]	new[238]|new[240]	_	_
34-27	4716-4717	4	substance[238]|person[240]|quantity	new[238]|new[240]|new	_	_
34-28	4718-4719	)	substance[238]|person[240]	new[238]|new[240]	_	_
34-29	4720-4722	-3	substance[238]|person[240]|abstract[243]	new[238]|new[240]|new[243]	_	_
34-30	4723-4724	,	substance[238]|person[240]|abstract[243]	new[238]|new[240]|new[243]	_	_
34-31	4725-4754	6-anhydro-α-D-galactopyranose	substance[238]|person[240]|abstract[243]|animal	new[238]|new[240]|new[243]|new	_	_
34-32	4755-4756	,	_	_	_	_
34-33	4757-4759	is	_	_	_	_
34-34	4760-4764	used	_	_	_	_
34-35	4765-4767	as	_	_	_	_
34-36	4768-4769	a	_	_	_	_
34-37	4770-4777	gelling	_	_	_	_
34-38	4778-4781	and	_	_	_	_
34-39	4782-4793	stabilizing	_	_	_	_
34-40	4794-4799	agent	_	_	_	_
34-41	4800-4802	in	_	_	_	_
34-42	4803-4806	the	abstract[246]	giv[246]	_	_
34-43	4807-4811	food	substance|abstract[246]	giv|giv[246]	coref	35-19
34-44	4812-4820	industry	abstract[246]	giv[246]	_	_
34-45	4821-4822	.	_	_	_	_

#Text=In addition , furcellaran can form complexes with various proteins , which can be used for encapsulation in food and agriculture applications .
35-1	4823-4825	In	_	_	_	_
35-2	4826-4834	addition	_	_	_	_
35-3	4835-4836	,	_	_	_	_
35-4	4837-4848	furcellaran	substance	giv	coref	37-1[259_0]
35-5	4849-4852	can	_	_	_	_
35-6	4853-4857	form	_	_	_	_
35-7	4858-4867	complexes	substance[248]	new[248]	_	_
35-8	4868-4872	with	substance[248]	new[248]	_	_
35-9	4873-4880	various	substance[248]|substance[249]	new[248]|giv[249]	coref	36-4[255_249]
35-10	4881-4889	proteins	substance[248]|substance[249]	new[248]|giv[249]	_	_
35-11	4890-4891	,	_	_	_	_
35-12	4892-4897	which	_	_	_	_
35-13	4898-4901	can	_	_	_	_
35-14	4902-4904	be	_	_	_	_
35-15	4905-4909	used	_	_	_	_
35-16	4910-4913	for	_	_	_	_
35-17	4914-4927	encapsulation	abstract[250]	giv[250]	coref	37-21[0_250]
35-18	4928-4930	in	abstract[250]	giv[250]	_	_
35-19	4931-4935	food	abstract[250]|substance|abstract[253]	giv[250]|giv|new[253]	_	_
35-20	4936-4939	and	abstract[250]|abstract[253]	giv[250]|new[253]	_	_
35-21	4940-4951	agriculture	abstract[250]|abstract|abstract[253]	giv[250]|new|new[253]	_	_
35-22	4952-4964	applications	abstract[250]|abstract[253]	giv[250]|new[253]	_	_
35-23	4965-4966	.	_	_	_	_

#Text=The interactions between proteins and polysaccharides can lead to the creation of completely new materials .
36-1	4967-4970	The	abstract[254]	giv[254]	_	_
36-2	4971-4983	interactions	abstract[254]	giv[254]	_	_
36-3	4984-4991	between	abstract[254]	giv[254]	_	_
36-4	4992-5000	proteins	abstract[254]|substance[255]	giv[254]|giv[255]	_	_
36-5	5001-5004	and	abstract[254]|substance[255]	giv[254]|giv[255]	_	_
36-6	5005-5020	polysaccharides	abstract[254]|substance[255]|substance	giv[254]|giv[255]|giv	_	_
36-7	5021-5024	can	_	_	_	_
36-8	5025-5029	lead	_	_	_	_
36-9	5030-5032	to	_	_	_	_
36-10	5033-5036	the	event[257]	new[257]	_	_
36-11	5037-5045	creation	event[257]	new[257]	_	_
36-12	5046-5048	of	event[257]	new[257]	_	_
36-13	5049-5059	completely	event[257]|substance[258]	new[257]|giv[258]	_	_
36-14	5060-5063	new	event[257]|substance[258]	new[257]|giv[258]	_	_
36-15	5064-5073	materials	event[257]|substance[258]	new[257]|giv[258]	_	_
36-16	5074-5075	.	_	_	_	_

#Text=Negatively-charged furcellaran can act as a film-forming matrix in active , biopolymer films and as a carrier material in the encapsulation process .
37-1	5076-5094	Negatively-charged	substance[259]	giv[259]	_	_
37-2	5095-5106	furcellaran	substance[259]	giv[259]	_	_
37-3	5107-5110	can	_	_	_	_
37-4	5111-5114	act	_	_	_	_
37-5	5115-5117	as	_	_	_	_
37-6	5118-5119	a	_	_	_	_
37-7	5120-5132	film-forming	_	_	_	_
37-8	5133-5139	matrix	_	_	_	_
37-9	5140-5142	in	_	_	_	_
37-10	5143-5149	active	object[261]	giv[261]	_	_
37-11	5150-5151	,	object[261]	giv[261]	_	_
37-12	5152-5162	biopolymer	person|object[261]	giv|giv[261]	_	_
37-13	5163-5168	films	object[261]	giv[261]	_	_
37-14	5169-5172	and	_	_	_	_
37-15	5173-5175	as	_	_	_	_
37-16	5176-5177	a	_	_	_	_
37-17	5178-5185	carrier	_	_	_	_
37-18	5186-5194	material	_	_	_	_
37-19	5195-5197	in	_	_	_	_
37-20	5198-5201	the	event[263]	new[263]	_	_
37-21	5202-5215	encapsulation	abstract|event[263]	giv|new[263]	_	_
37-22	5216-5223	process	event[263]	new[263]	_	_
37-23	5224-5225	.	_	_	_	_
